Clinical Trial Update: A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation study of FP-045 in patients with Fanconi Anemia has been withdrawn (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fanconi Anemia

Drugs mentioned

• FP-045

Snippet

Sponsor: Foresee Pharmaceuticals Co., Ltd. | Conditions: Fanconi Anemia | Phase 1, Phase 2 | Status: WITHDRAWN